Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Natalizumab in SPMS
NCT01416181Phase 3Terminated
- Sponsor
- Biogen
- Start
- Sep 2011
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of natalizumab in secondary-progressive multiple sclerosis (SPMS), sponsored by Biogen. Started Sep 2011; status: terminated.
02
Drugs
natalizumab
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT01416181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01416181.